Joubert Michael, Benhamou Pierre-Yves, Schaepelynck Pauline, Hanaire Hélène, Catargi Bogdan, Farret Anne, Fontaine Pierre, Guerci Bruno, Reznik Yves, Jeandidier Nathalie, Penfornis Alfred, Borot Sophie, Chaillous Lucy, Franc Sylvia, Serusclat Pierre, Kherbachi Yacine, Bavière Eric, Detournay Bruno, Simon Pierre, Charpentier Guillaume
Diabetes Care Unit, Caen University Hospital, Caen, France.
Department of Diabetology, Pôle DigiDune, University Hospital, Grenoble, France.
J Diabetes Sci Technol. 2019 Nov;13(6):1161-1168. doi: 10.1177/1932296819834054. Epub 2019 Mar 12.
Benefits of telemedicine have been proven in the field of diabetes. Among a number of technical solutions, Diabeo® has been studied in both type 1 and type 2 diabetes with intensive insulin therapy. This digital therapeutic system contains a self-monitoring glucose logbook and offers automated insulin dose recommendations thanks to a fully customizable algorithm. In addition, the cloud-based dedicated software also has features to facilitate remote monitoring, including a platform for diabetes nurses who perform coaching and treatment adjustment. A detailed description of this telemedicine system is provided, as well as results of completed clinical studies. In particular, TeleDiab 1's positive results on HbA1c in type 1 diabetes are detailed. We conclude with a discussion of the role of this telemedicine system within the landscape of mobile apps for diabetes.
远程医疗的益处已在糖尿病领域得到证实。在众多技术解决方案中，Diabeo®已在1型和2型糖尿病强化胰岛素治疗中进行了研究。这个数字治疗系统包含一个自我监测血糖日志，并借助一个完全可定制的算法提供自动胰岛素剂量建议。此外，基于云的专用软件还具备便于远程监测的功能，包括为进行指导和治疗调整的糖尿病护士提供的一个平台。文中提供了这个远程医疗系统的详细描述以及已完成临床研究的结果。特别是，详细介绍了TeleDiab 1对1型糖尿病患者糖化血红蛋白（HbA1c）的积极效果。最后，我们讨论了这个远程医疗系统在糖尿病移动应用领域中的作用。
